Postoperative metastasis prediction based on portal vein circulating t | CMAR - Dove Medical Press

Lianyuan Tao,^1,2 Li Su,³ Chunhui Yuan,¹ Zhaolai Ma,¹ Lingfu Zhang,¹ Shiping Bo,⁴ Yunyun Niu,⁴ Sijia Lu,⁴ Dianrong Xiu¹

¹Department of General Surgery, Peking University Third Hospital, Beijing 100191, People’s Republic of China; ²Department of Hepatobiliary Surgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan 450003, People’s Republic of China; ³Medical and Health Analytical Center, Peking University Health Science Center, Beijing 100191, People’s Republic of China; ⁴Department of Clinical Research, Yikon Genomics Co. Ltd., Shanghai, People’s Republic of China

Purpose: The aim of this study was to evaluate the value of flow cytometry (FCM) detection of portal vein circulating tumor cells (CTCs) in predicting postoperative metastasis.
Methods: Samples of portal venous blood and peripheral blood were collected from 39 patients during surgery, and CTCs were detected by FCM, with confirmation by laser confocal microscopy and single-cell sequencing.
Results: Among all patients, a portal EpCAM+CD45- percentage ≥24.5×10⁻⁴ (P=0.06), peripheral EpCAM+CD45- count ≥97/5 mL (P=0.034), peripheral EpCAM+CD45- percentage ≥4.4×10⁻⁴ (P=0.042), and CA242≥3.5 U/mL (P=0.027) were significant predictors of metastasis. Further analysis showed that the portal EpCAM+CD45- ratio ≥24.5×10⁻⁴ is a predictor of metastasis (P=0.025) in pancreatic cancer after curative resection.
Conclusion: CTCs detected by FCM in portal venous blood are of significant value for the prediction of postoperative metastasis in pancreatic or periampullary tumors.

Keywords: circulating tumor cells, flow cytometry, portal vein, pancreatic cancer, metastases
 

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Let's block ads! (Why?)

Read Full Article Postoperative metastasis prediction based on portal vein circulating t | CMAR - Dove Medical Press : https://ift.tt/2ZCd3ey

Bagikan Berita Ini